VIR 주요 통계
고가
9.09
개시가
8.82
거래량
1.68M
저가
8.77
전일 종가
8.69
거래대금
14.99M
52주 최고가
11.66
상대 거래량
1.022
변동폭 (%)
3.62%
52주 최저가
4.16
회전율
1.00%
시가총액
1.46B
PER (TTM)
--
PER (연간)
2.234
PBR
1.8
PSR
22.38
주당순이익(EPS)
-3.137
배당금(TTM)
0
배당수익률
0.00%
발행주식수
168.65M
통화 단위
USD
VIR 가격 수익률
7 일
30 일
90 일
180 일
연초 이후
1 년
VIR 자금 흐름 분포
VIR 일일 공매도 거래량
VIR 공매도 잔고 내역
VIR 주식 스냅샷
As of 2026-07-28, the Vir Biotechnology, Inc. (VIR) stock price today is 8.8. Based on this price, the company has a market capitalization of $1.46B, with a P/E ratio of --.
On 2026-07-28, VIR traded between 8.77 and 9.09. Today’s stock price is 0.34% above the daily low and 3.19% below the daily high, placing VIR 하단 부근 its most recent trading range.
Trading volume currently stands at 1.68M, compared with an average daily volume of 1.65M. This suggests that trading activity is 평소 수준과 대체로 비슷한 than usual.
Over the past year, Vir Biotechnology, Inc. shares have traded between 4.16 and 11.66. At today’s price, VIR is 111.54% above its 52-week low and 24.53% below its 52-week high.
VIR 관련 뉴스
소개 VIR
회사 이름
Vir Biotechnology, Inc.
섹터
Health Technology
산업
Biotechnology
거래소
Nasdaq
직원 수
367
랏 크기
100
공식 웹사이트
통화 단위
USD
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Related Stocks
